A non-aluminum containing mixed metal compound for pharmaceutical use, which
may,
for example, be a mixed metal hydroxy carbonate containing magnesium and iron,
and may have a hydrotalcite structure, preferably a non-aged hydrotalcite structure.
Other metals, including, for example, calcium, lanthanum and cerium, may also be
used. Metal sulphate compounds, especially calcium sulphate, lanthanum sulphate
and/or cerium sulphate, compounds are also useful. The mixed metal compounds have
a phosphate binding capacity of at least 30%, by weight, based on the test methods
1, 2 or 3, described in the specification, over a pH range from 3 to 7, such as
from 2 to 8. The compound is especially useful in the treatment of hyperphosphataemia.
